Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biogen : Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimer's Disease

11/22/2021 | 11:15am EST

Today, Biogen and Eisai announced that the Journal of the American Medical Association (JAMA) Neurology published a peer-reviewed paper about findings around amyloid-related imaging abnormalities (ARIA) in the Phase 3 trials of ADUHELM (aducanumab-avwa). The publication notes that the importance of the manuscript is, "The EMERGE and ENGAGE phase 3 randomized clinical trials of aducanumab provide a robust data set to characterize amyloid-related imaging abnormalities (ARIA) that occur with treatment with aducanumab, an amyloid-β (Aβ)-targeting monoclonal antibody, in patients with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia."

The combined studies consisted of a total of 3,285 participants with Alzheimer's disease who received 1 or more doses of placebo (n=1087) or aducanumab (n=2198; 2752 total person-years of exposure) during the placebo-controlled period.
The complete publication is available on the JAMA Neurology website.

Disclaimer

Biogen Inc. published this content on 22 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 November 2021 16:14:03 UTC.


© Publicnow 2021
All news about BIOGEN INC.
12:21pBarclays Adjusts Biogen's Price Target to $244 from $280, Keeps Equalweight Rating
MT
01/19BIOGEN : to Report Fourth Quarter and Full Year 2021 Financial Results February 3, 2022
PU
01/18Morgan Stanley Adjusts Price Target for Biogen to $360 From $363, Maintains Overweight ..
MT
01/18HC Wainwright Adjusts Biogen's Price Target to $270 from $452, Keeps Buy Rating
MT
01/18Biogen on Cusp of 'Change' in Wedbush View as Medicare's Proposed Plan for Alzheimer's ..
MT
01/14BofA Securities Adjusts Biogen's Price Target to $245 From $275, Maintains Neutral Rati..
MT
01/14California Court Of Appeal Affirms Injunction Barring Netflix From Poaching Fox Executi..
AQ
01/13S&P Downgrades Biogen Rating To 'BBB+' From 'A-' On Declining Sales, Lower Growth Prosp..
MT
01/13Biogen Wants Final Decision on Aduhelm Alzheimer's Drug to be 'Coverage With Restrictio..
MT
01/13Biogen eyes potential acquisitions - Stat News
RE
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2021 10 870 M - -
Net income 2021 1 765 M - -
Net Debt 2021 2 281 M - -
P/E ratio 2021 21,2x
Yield 2021 -
Capitalization 33 185 M 33 185 M -
EV / Sales 2021 3,26x
EV / Sales 2022 3,12x
Nbr of Employees 9 100
Free-Float -
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 34
Last Close Price 225,91 $
Average target price 286,14 $
Spread / Average Target 26,7%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Mark Hernon Chief Information Officer & Senior Vice President
Alphonse Galdes EVP-Pharmaceutical Operations & Technology
Sector and Competitors